Oncology clinical trial sites sit at one of the most administratively complex intersections in clinical research. Solid tumor studies using RECIST (Response Evaluation Criteria in Solid Tumors) criteria require imaging assessments at defined treatment cycles, precise documentation of tumor measurements, specimen collection and shipment for correlative science, and — for patients without remaining standard options — compassionate use or expanded access programs that carry their own regulatory documentation requirements.
For coordinators managing multiple active oncology protocols at a single site, the documentation volume is staggering. A coordinator handling three concurrent solid tumor trials may be tracking 30–45 subjects across different treatment schedules, each with cycle-specific imaging windows, lab collections, and response assessment documentation. Adding compassionate use requests, which require FDA correspondence and sponsor coordination, creates a workload that exceeds what one or two coordinators can manage without dedicated administrative support.
RECIST Assessment Scheduling: Precision Under Pressure
RECIST 1.1 criteria require that target and non-target lesion assessments be conducted at specified timepoints — typically every two to three treatment cycles — and that the results be documented against baseline measurements established at study entry. Coordinators must schedule imaging (CT, MRI, or PET-CT depending on the protocol), ensure the scans are conducted within the assessment window, and confirm that radiology reports are available for the investigator's response evaluation before the next treatment decision.
An oncology trial VA maintains the imaging schedule matrix for all enrolled subjects, sends advance scheduling requests to radiology, confirms appointment dates against treatment cycle windows, and tracks whether scans have been completed and reports received. When windows are at risk of being missed — due to subject hospitalization, scheduling conflicts, or imaging department delays — the VA flags the issue to the coordinator with enough lead time to reschedule without generating a protocol deviation.
Correlative Specimen Shipment: A Logistics Function With Scientific Stakes
Most oncology trials include correlative science components — tumor biopsies, circulating tumor DNA (ctDNA) samples, immunophenotyping panels, or archival tissue requests — that are shipped to central or specialty labs for analysis. Managing this logistics chain requires tracking collection schedules, maintaining chain-of-custody documentation, coordinating with the site's pathology or biorepository, and ensuring specimens are shipped per protocol-specified conditions (frozen, ambient, or fixed) within required timeframes.
Shipment coordination failures — wrong temperature, wrong timepoint, missing chain-of-custody documentation — result in sample rejection, which can compromise correlative endpoints that are critical to the study's scientific objectives and future regulatory filings. An oncology trial VA owns the shipment coordination function: generating collection reminders, preparing shipment manifests, coordinating courier pickups, and tracking receipt confirmation from the receiving lab.
Compassionate Use Documentation: High Stakes, High Volume
Compassionate use (expanded access) programs allow patients who do not qualify for or cannot access a clinical trial to receive investigational therapy. At oncology sites treating patients with advanced disease, compassionate use requests are common — and the documentation requirements are substantial.
The VA maintains compassionate use case files, tracks FDA correspondence timelines (emergency IND requests require 30-day FDA review; emergency requests can be authorized by phone within hours but require follow-up documentation), coordinates with the sponsor's medical monitor, and ensures IRB notification and approval are documented per applicable regulations. For sites with active compassionate use patients, the VA also tracks treatment and safety reporting requirements, which mirror those of enrolled trial subjects.
The Burnout Cost of Not Having Support
The Oncology Nursing Society (ONS) reported in its 2024 workforce survey that burnout among oncology research nurses and coordinators has reached a five-year high, with documentation burden ranking second only to emotional strain from patient outcomes. High-volume cancer centers running five or more concurrent trials are the hardest hit.
A dedicated oncology trial VA removes the most time-consuming administrative functions from coordinator and nursing staff, creating the operational breathing room that directly reduces burnout risk and improves retention. For oncology research programs, that retention translates to protocol expertise, subject relationship continuity, and fewer training cycles after turnover.
Oncology trial sites seeking experienced administrative support can learn more at Stealth Agents.
Sources
- American Society of Clinical Oncology (ASCO), Research Site Workforce Survey 2024
- Oncology Nursing Society (ONS), Burnout and Workforce Survey 2024
- RECIST 1.1 Criteria, Eisenhauer et al., European Journal of Cancer 2009
- FDA Guidance on Expanded Access to Investigational Drugs for Treatment Use